All In Biotech

Drug Trial Radar · NCT06737081

SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies

A Parallel, Open-label Phase II Clinical Study of Enarodustat (SAL-0951) Tablets in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies

Last checked: Nov 20, 2026Latest source record: Dec 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Sep 14, 2024

Primary completion

Dec 31, 2025

Study completion Jun 30, 2026

Sponsor

Sponsor type
Industry
First posted
Dec 17, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of SAL-0951 in the treatment of chemotherapy-induced anemia (CIA) in patients with non-myeloid malignancies

Conditions

  • Anemia

Interventions

  • SAL-0951 tablets 4mgDrug

    initial phase:4mg QD subsequent phase:1mg~8mg QD,adjust the dose based on hemoglobin concentration level every 4 weeks

  • SAL-0951 tablets 5mgDrug

    initial phase:5mg QD subsequent phase:1mg~8mg QD,adjust the dose based on hemoglobin concentration level every 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse events by CTCAE5.0Time frame: through study completion, an average of 4 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Chest Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.